about
Nonionic surfactant vesicles in ocular delivery: innovative approaches and perspectivesOcular drug delivery.Bioadhesive hyaluronan-chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue.An evaluation of Retaine™ ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eyeTargeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA.Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb.Ocular drug delivery: nanomedicine applications.Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assayToxicity of nanomaterials to the eye.Topical drug delivery using chitosan nano- and microparticles.Challenges in neuroprotective nanomedicine development: progress towards noninvasive gene therapy of glaucoma.Recent advances in ocular drug delivery.Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery.In vitro testing of thiolated poly(aspartic acid) from ophthalmic formulation aspects.Minimally invasive microneedles for ocular drug delivery.siRNA-loaded liposomes: Inhibition of encystment of Acanthamoeba and toxicity on the eye surface.A novel eye drop of alpha tocopherol to prevent ocular oxidant damage: improve the stability and ocular efficacy.Relevance of Lipid-Based Products in the Management of Dry Eye Disease.Hybrid nanoparticle design based on cationized gelatin and the polyanions dextran sulfate and chondroitin sulfate for ocular gene therapy.A nanomedicine to treat ocular surface inflammation: performance on an experimental dry eye murine model.Influence of borneol on in vitro corneal permeability and on in vivo and in vitro corneal toxicity.Tuning the Endocytosis Mechanism of Zr-Based Metal-Organic Frameworks through Linker Functionalization.Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability.When nanotechnology meets the ocular surfaceCationic Gelatin Nanoparticles for Drug Delivery to the Ocular Surface:In VitroandIn VivoEvaluation
P2860
Q26999057-B0943CBE-17F8-42B9-94D0-4C9AB06742DDQ30475605-237A4EB4-A0DC-4C68-B887-392E620E1DBEQ33321483-3D22D826-E51F-46E2-82D9-419961B4F9BDQ35094304-D9EB84D7-DB47-4445-B79E-40E0727573A8Q35100982-947575CC-5DD8-457D-AFCF-648788DA6E29Q35854966-BD7A1240-03E7-4BA6-866C-F5F26359FC5BQ36918036-FE52F922-E016-42CD-BD35-1C32E8E67953Q37318278-92D61699-2027-4308-8A72-A6C5D72B099BQ37676123-9F80DC5B-0E9C-4D0B-9DA3-0FD24A28A0EDQ38024402-BDF69EDF-E50A-4F53-B879-96485BFDD227Q38030642-CE9312D3-823A-4D60-8CB4-54A6ECA5F05CQ38059884-52976134-4B88-4EE0-86E9-097476FF4A93Q38133883-46B0FD2A-1BDE-4739-B780-019D359687B5Q38820385-A0A1C9B7-429F-4AD6-9F31-FA7030CB2A2AQ38916649-5DCF60ED-AEDF-47CC-AD50-44748931314CQ40353236-336A082C-D175-440C-9384-7011DB7D8799Q40573088-70D02A56-39CA-46EC-805D-9FCF6861A9A5Q43119649-0B80241F-9A37-406C-BF6D-7D2182ACE799Q45869238-CD437B49-1F8E-4D41-BFA0-3B239742743FQ45880556-0C5D9B10-54BF-42C0-AC23-8D50E3E843A4Q45934022-1E431672-C444-4F33-BB3F-D2A989D2D727Q47660817-8BF1F1EC-7A64-44D2-8BE4-BDE2004A4055Q51787921-FAA5A57D-5B32-49E9-B162-FAAD97C8CC2BQ57381955-B2F1329B-0689-411F-AF58-91090E8ABE32Q59016771-116AAF6C-CD44-46C5-A809-5FCD1FAFC7CF
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cationic vectors in ocular drug delivery.
@ast
Cationic vectors in ocular drug delivery.
@en
type
label
Cationic vectors in ocular drug delivery.
@ast
Cationic vectors in ocular drug delivery.
@en
prefLabel
Cationic vectors in ocular drug delivery.
@ast
Cationic vectors in ocular drug delivery.
@en
P2093
P2860
P1476
Cationic vectors in ocular drug delivery.
@en
P2093
Catherine Dubernet
Gregory Lambert
Laura Rabinovich-Guilatt
P2860
P304
P356
10.1080/10611860400015910
P577
2004-09-01T00:00:00Z